Compare Ambarella Inc (AMBA) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ambarella Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Ambarella Inc trades at $74.16 (market cap $3.39B), while Vertex Pharmaceuticals Incorporated trades at $477.65 (market cap $123.19B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 36.3× Ambarella Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Ambarella Inc nearer its low. Which is the better fit depends on your goals.
| AMBA | VRTX | |
|---|---|---|
Market Cap | $3.39B | $123.19B |
Sector | Technology | Health |
52-Week High | $95.51 | $529.59 |
52-Week Low | $48.65 | $366.54 |
Enterprise Value | $3.13B | $117.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ambarella (AMBA) trades at $77.30, down 1.38% on the day, with a bullish technical setup supported by moving averages and key resistance at $81. The company reported three consecutive quarterly EPS beats, with Q1 2027 earnings of $0.11 meeting estimates, while revenue grew 16.9% year-over-year to $100.4 million. A major catalyst is the $800+ million long-term edge AI agreement with Hanwha, signaling strong demand in physical AI markets. However, net income remains negative at -$117.13 million for 2025, though margins are improving.
Outlook: Wall Street is bullish with a $108.67 consensus price target (40% upside), driven by edge AI adoption and auto sector growth. Risks include persistent losses, competitive pressure from larger chipmakers, and execution challenges in scaling new AI contracts. The stock's valuation at 8.21x sales appears reasonable if revenue acceleration continues, but profitability remains key for sustained gains.
Vertex Pharmaceuticals (VRTX) trades at $485.39, down 2.24% today but maintains a bullish technical trend with strong support at $486. The company reported robust 2025 results with $12.00B revenue and $3.95B net income, though margins dipped slightly. Recent news highlights a strategic $10B acquisition of Crinetics Pharmaceuticals, expanding its endocrinology portfolio with potential $5B peak sales. Analyst consensus remains strongly bullish with an 83.9% buy rating and $526.50 price target.
Outlook is positive driven by earnings growth and strategic acquisitions, but risks include integration challenges from the Crinetics deal and reliance on cystic fibrosis treatments. The stock offers upside to consensus targets but faces volatility near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ambarella Inc
Ambarella is a semiconductor company specializing in low-power video compression and computer vision processors. Its chips power AI cameras for security, automotive safety, and robotics applications.
Read more on AMBA →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
